BenchSci is an AI-powered search engine for biological products. It empowers scientists with the world’s most advanced biomedical AI to run more successful experiments.
BenchSci exponentially increases the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence to run more successful experiments.
BenchSci was founded in 2015 by Tom Leung, David Q. Chen, Elvis Wianda, and Liran Belenzon. The company is headquartered in Toronto, Ontario, Canada.
BenchSci uses machine learning to diagnose pharmaceutical R&D health from hidden patterns in procurement data.
BenchSci is the only company that can diagnose and resolve pharmaceutical R&D inefficiency resulting from suboptimal reagent selection. BenchSci’s technology provides a unique value proposition for this market, enabling academic researchers to spend less time searching for antibodies and more time working on their experiments.
BenchSci’s image recognition technology extracts antibody specifications from published experiments using AI — not just vendor names, product names, or SKUs. The system applies bioinformatics and ontologies to link antibodies to use cases while providing access to catalog data of more than 7.7 million products from 231 vendors.
BenchSci now optimizes reagent procurement and experimental success in 15 of the top 20 pharmaceutical companies and over 3,600 leading academic centers globally. The company's customers include 14 pharmaceutical companies (including 7 of the world’s top 10), and 910 academic research institutions (including Harvard, UCLA, Stanford, and MD Anderson).
BenchSci is backed by F-Prime Capital, Gradient Ventures, Inovia Capital, Northleaf Capital Partners, Golden Ventures and others. The company raised $22M in a Series B financing on Feb 04, 2020. This brings BenchSci’s total funding to $45M to date.